NW
Therapeutic Areas
Oxford Biomedica Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Kymriah (Novartis) - LV Vector Supply | B-cell Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-Cell Lymphoma (DLBCL) | Approved |
Leadership Team at Oxford Biomedica
DR
Dr. Roch Doliveux
Chair of the Board of Directors
DF
Dr. Frank Mathias
Chief Executive Officer
PS
Peter Soelkner
Vice Chair of the Board of Directors
PD
Professor Dame Kay Davies
Senior Independent Director
CB
Colin Bond
Independent Non-Executive Director
DL
Dr. Lucinda Crabtree
Chief Financial Officer
LE
Laurence Espinasse
Non-Executive Director
NP
Namrata P Patel
Independent Non-Executive Director
DH
Dr. Heather Preston
Independent Non-Executive Director
LD
Lisa Doman
Chief People Officer